Skip to content
10-Q

Quarterly Report

Landos Biopharma, Inc.

0000950170-23-021517

← back to feed
Filed
May 12, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 5, 2023 31.17M sh
Capex Q1 2023 · Mar 31, 2023 $0
Capex Q1 2023 · Mar 31, 2022 $7K
Cash And Equivalents Q1 2023 · Mar 31, 2023 $45.24M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $36.64M
Current Liabilities Q1 2023 · Mar 31, 2023 $4.16M
Current Liabilities Q1 2023 · Dec 31, 2022 $6.12M
Total Liabilities Q1 2023 · Mar 31, 2023 $4.16M
Total Liabilities Q1 2023 · Dec 31, 2022 $6.12M
Current Assets Q1 2023 · Mar 31, 2023 $51.18M
Current Assets Q1 2023 · Dec 31, 2022 $45.25M
Total Assets Q1 2023 · Mar 31, 2023 $51.18M
Total Assets Q1 2023 · Dec 31, 2022 $45.25M
Shares Diluted Q1 2023 · Mar 31, 2022 40.25M sh
Stock Repurchased Q1 2023 · Mar 31, 2022 $0
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$16.5M
Stockholders Equity Q1 2023 · Mar 31, 2022 $62.1M
Stockholders Equity Q1 2023 · Dec 31, 2021 $76.27M
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.37
Eps Basic Q1 2023 · Mar 31, 2022 −$0.37
Sga Expense Q1 2023 · Mar 31, 2022 $4.15M
Rd Expense Q1 2023 · Mar 31, 2022 $10.8M
Net Income Q1 2023 · Mar 31, 2022 −$14.86M
Operating Income Q1 2023 · Mar 31, 2022 −$14.95M